本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江尖峰集团股份有限公司2025 年第一季度报告 证券代码：600668 证券简称：尖峰集团 浙江尖峰集团股份有限公司 2025 年第一季度报告 重要内容提示 √适用 □不适用 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 1 / 12 单位：万元 币种：人民币 项目 本报告期 上年同期 本报告期比上年同 期增减变动幅度 (%) 营业收入 58,414.29 60,166.89 -2.91 归属于上市公司股东的净利润 58,227.47 242.83 23,878.70 归属于上市公司股东的扣除非 经常性损益的净利润 -8,930.84 -557.43 不适用 经营活动产生的现金流量净 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥48,950,596.21, a decrease of 58.31% compared to ¥117,418,731.61 in the same period last year[4] - The net profit attributable to shareholders was -¥1,288,344.63, representing a decline of 105.79% from ¥22,233,383.94 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,432,773.63, a decrease of 135.90% compared to ¥17,919,215.96 in the previous year[4] - The basic and diluted earnings per share were both -¥0.01, down 108.33% from ¥0.12 in the same period last year[4] - The weighted average return on equity decreased by 1.19 percentage points to -0.07% from 1.12% year-on-year[4] - The total comprehensive income attributable to the parent company was -1,288,344.63 CNY, contrasting with 22,233,383.94 CNY in the previous period, marking a substantial decline[20] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥32,264,160.61, compared to -¥21,253,398.66 in the same period last year, indicating a worsening cash flow situation[4] - The company's cash and cash equivalents decreased to CNY 101,949,711.30 from CNY 389,050,268.24[14] - Current assets totaled CNY 839,446,941.90 as of March 31, 2025, down from CNY 880,158,695.97 at the end of 2024[14] - The company's total assets as of March 31, 2025, were CNY 2,087,319,802.14, a decrease from CNY 2,121,994,903.72 as of December 31, 2024[17] - The company’s cash flow from financing activities was negative at -117,605.16 CNY, primarily due to share repurchase payments[24] Shareholder Information - The company plans to distribute a cash dividend of ¥3.25 per 10 shares, totaling approximately ¥59,609,046.25, which accounts for 98.85% of the annual net profit attributable to shareholders[12] - The total number of ordinary shareholders at the end of the reporting period was 8,307[9] Operating Costs and Investments - Total operating costs for Q1 2025 were CNY 56,641,872.62, down 42.0% from CNY 97,522,479.92 in Q1 2024[18] - The company made significant investments totaling 492,967,055.70 CNY in Q1 2025, compared to 150,000,000.00 CNY in Q1 2024, indicating a strategic focus on expansion despite cash flow challenges[23] Government Support - The company received government subsidies amounting to ¥2,774,274.92 during the reporting period, which are closely related to its normal business operations[6] Inventory and Liabilities - Inventory increased to CNY 90,084,494.41 from CNY 82,024,423.44, reflecting a growth of 9.5%[14] - Total liabilities decreased to CNY 163,315,773.00 from CNY 197,240,946.08, a reduction of 17.2%[16] Research and Development - Research and development expenses for Q1 2025 were CNY 3,573,448.81, a decrease of 33.3% from CNY 5,362,003.26 in Q1 2024[19]

Financial Performance - The company's operating revenue for Q1 2025 was ¥119,939,565.89, representing a 5.46% increase compared to ¥113,729,714.98 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥16,801,086.49, an improvement from a loss of ¥17,919,119.60 year-over-year[4] - The company's overall revenue increased by 5.46% year-on-year, primarily due to a significant rise in the shipment volume of lithium battery coating materials[12] - The net profit attributable to shareholders was -16.80 million RMB, mainly due to insufficient production rates and increased expenses in the first quarter[12] - Net loss for Q1 2025 was CNY 17,183,537.50, slightly improved from a net loss of CNY 17,957,692.05 in Q1 2024[21] Cash Flow - The net cash flow from operating activities was negative at ¥61,237,386.34, worsening from a negative cash flow of ¥34,281,220.82 in the previous year[4] - Operating cash flow for Q1 2025 was negative CNY 61,237,386.34, worsening from negative CNY 34,281,220.82 in Q1 2024[24] - The cash and cash equivalents net increase was -$308.81 million, compared to -$263.12 million in the prior period, indicating a worsening cash position[25] - The company's cash and cash equivalents decreased to 276.61 million RMB from 593.90 million RMB, indicating a decline of approximately 53.4%[16] - Cash outflow for investment activities totaled $587.63 million, compared to $823.47 million, showing a reduction of about 29%[25] Assets and Liabilities - Total assets increased by 5.04% to ¥3,386,072,369.94 from ¥3,223,564,340.39 at the end of the previous year[5] - As of March 31, 2025, total assets amounted to 3.39 billion RMB, up from 3.22 billion RMB at the end of 2024[16][17] - The company's total liabilities increased to CNY 1,190,756,312.81 in the latest reporting period, up from CNY 1,011,036,048.94[18] - Total equity attributable to shareholders decreased to CNY 2,185,396,985.45 from CNY 2,202,205,824.91[18] Expenses - Research and development expenses totaled ¥15,328,948.02, accounting for 12.78% of operating revenue, down from 13.95% in the previous year[5] - Total operating costs for Q1 2025 were CNY 145,026,145.99, up from CNY 140,427,876.16 in Q1 2024, reflecting a 3.7% increase[20] - The company reported a decrease in sales expenses from CNY 4,428,108.03 in Q1 2024 to CNY 2,111,249.12 in Q1 2025, a reduction of 52.4%[20] - Research and development expenses remained stable at CNY 15,328,948.02 in Q1 2025, compared to CNY 15,864,211.24 in Q1 2024[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,127[9] - The top shareholder, Jiang Xuexin, controls 23.56% of the company's shares, while he and his spouse, Wang Yajuan, collectively control 27.82%[11] Government Support and Market Strategy - The company received government subsidies amounting to ¥2,568,727.84, which positively impacted the financial results[6] - The company is focusing on improving cash flow management, particularly through the collection of supply chain notes[7] - The company is focused on expanding its market presence and enhancing product development in the lithium battery sector[12] - The company has implemented a market value management system effective from April 28, 2025, to enhance investment value and protect investor rights[12]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 200,512,774.6, a decrease of 15.14% compared to CNY 236,291,119.74 in the same period last year[4] - Net profit attributable to shareholders was CNY 6,045,622.11, down 59.67% from CNY 14,991,448.88 year-on-year[4] - The basic earnings per share decreased by 60.00%, from CNY 0.05 to CNY 0.02[5] - The weighted average return on equity fell by 0.60 percentage points, from 1.02% to 0.42%[5] - Total revenue for Q1 2025 was CNY 200,512,774.60, a decrease of 15.1% compared to CNY 236,291,119.74 in Q1 2024[18] - Gross profit margin for Q1 2025 was approximately 0.83%, compared to 5.5% in Q1 2024, indicating a significant decline in profitability[18] - Operating profit for Q1 2025 is CNY 6,863,099.91, down 61.3% from CNY 17,701,391.92 in the same period last year[19] - The company's total profit for Q1 2025 is CNY 7,173,808.64, a decrease of 59.5% from CNY 17,701,390.35 in Q1 2024[19] - Operating profit for Q1 2025 was CNY 7,210,534.80, down 60.1% from CNY 18,066,276.44 in Q1 2024[31] - Net profit for Q1 2025 was CNY 6,393,057.00, a decline of 58.3% compared to CNY 15,356,334.97 in Q1 2024[31] Cash Flow and Liquidity - The net cash flow from operating activities increased by 14.15%, reaching CNY 31,827,312.01 compared to CNY 27,882,016.81 in the previous year[4] - Cash flow from operating activities for Q1 2025 is CNY 31,827,312.01, an increase of 14.0% compared to CNY 27,882,016.81 in Q1 2024[24] - The company reported a net cash increase of CNY 30,441,801.10 in Q1 2025, compared to CNY 21,080,659.38 in Q1 2024[25] - The cash and cash equivalents balance at the end of Q1 2025 is CNY 467,390,421.08, up from CNY 362,669,274.52 a year earlier[25] - The net cash flow from financing activities was 0.00, suggesting no new debt or equity financing during the period[35] - The net increase in cash and cash equivalents for the period was 30,450,439.72, compared to 21,106,667.04 in the previous period, reflecting a significant increase[35] - The ending balance of cash and cash equivalents reached 466,273,262.54, up from 362,622,008.80 in the prior period, indicating strong liquidity[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,679,807,026.50, a slight decrease of 0.13% from CNY 1,682,074,313.80 at the end of the previous year[5] - Total assets as of March 31, 2025, were CNY 1,679,807,026.50, slightly down from CNY 1,682,074,313.80 at the end of 2024[15] - Total liabilities decreased to CNY 247,025,186.20 from CNY 255,338,095.61, a reduction of 3.2%[14] - Total liabilities decreased to CNY 246,108,224.36 from CNY 254,421,160.65, reflecting a reduction of 3.2%[28] - Shareholders' equity attributable to shareholders increased by 0.42%, from CNY 1,426,736,218.19 to CNY 1,432,781,840.30[5] - Shareholders' equity increased to CNY 1,432,781,840.30 from CNY 1,426,736,218.19, reflecting a growth of 0.4%[15] - The company's total equity increased to CNY 1,438,516,449.92 from CNY 1,432,123,392.92, showing a growth of 0.4%[28] Research and Development - R&D expenses for Q1 2025 were CNY 6,623,082.50, down 54.5% from CNY 14,485,934.33 in Q1 2024, indicating a significant reduction in investment in innovation[18] - Research and development expenses for Q1 2025 were CNY 6,623,082.50, significantly lower than CNY 14,485,934.33 in Q1 2024, indicating a reduction of 54.5%[30] Market and Product Development - The decline in net profit was primarily due to a decrease in revenue from direct and indirect exports of the company's products[7] - The company has not disclosed any new product developments or market expansion strategies in this report[7]

Financial Performance - The company's operating revenue for 2024 was CNY 1,198,238,535.39, a decrease of 11.66% compared to CNY 1,356,448,097.16 in 2023[26]. - The net profit attributable to shareholders for 2024 was CNY -100,660,051.84, representing a decline of 183.02% from CNY 121,249,399.50 in 2023[26]. - Basic earnings per share for 2024 were CNY -0.90, a significant drop of 184.11% compared to CNY 1.07 in 2023[27]. - The weighted average return on equity decreased to -5.19% in 2024, down 11.49 percentage points from 6.30% in 2023[27]. - The company reported a net cash flow from operating activities of CNY -156,549,765.40 for 2024, compared to CNY -84,061,904.21 in 2023[26]. - The company achieved operating revenue of 1,198.24 million RMB, a year-on-year decrease of 11.66%[35]. - The net profit attributable to shareholders was -100.66 million RMB, a year-on-year decrease of 183.02%[35]. - The gross margin improved by 1.12% to 27.76% due to enhanced management and cost control measures[36]. Research and Development - Research and development expenses increased significantly as the company pursued an integrated development strategy for raw material drugs[28]. - R&D investment for 2024 was 138.88 million RMB, accounting for 11.59% of operating revenue[38]. - The company has 8 formulation applications accepted by the National Medical Products Administration, with over 10 more planned for submission[36]. - The company established a synthetic biology research platform to enhance its product pipeline and competitiveness[39]. - The company is focusing on expanding its product portfolio in the anti-infection and anti-fungal categories to enhance market presence[111]. - The company plans to continue its investment in R&D to support the development of new drugs and improve existing formulations[112]. - The total R&D investment for 2024 was CNY 138.88 million, representing a 69.14% increase year-over-year and accounting for 11.59% of total revenue[112]. Market Position and Strategy - The company is positioned as a WHO-recommended supplier for Levofloxacin, facilitating its global market expansion[40]. - The company has established a competitive advantage in the production of 7-ACCA, a key intermediate for cephalexin, being one of the few in the industry capable of synthesizing it from penicillin[62]. - The company is actively extending its product line into ceftazidime and cefoperazone, with submissions for CDE approval already made[62]. - The company is focusing on expanding its integrated strategy of "raw materials + formulations" through the construction of convertible bond projects[64]. - The company aims to develop into an internationally leading pharmaceutical enterprise specializing in high-end raw materials, intermediates, and formulations[142]. - The company plans to launch new products in the next three to five years, focusing on high-end markets and obtaining relevant registrations[141]. Corporate Governance - The board of directors and supervisory board members have guaranteed the authenticity and completeness of the annual report[5]. - The company has established a robust internal control system to manage operational risks, consisting of decision-making, operational, and execution layers[165]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with all shareholders[164]. - The company held its first extraordinary general meeting of 2024 on April 1, where it approved a proposal to adjust the conversion price of bonds[166]. - The company plans to implement a restricted stock incentive plan in 2024, with related proposals to be discussed in upcoming shareholder meetings[167]. - The company is committed to enhancing investor relations and maintaining open communication channels with investors[164]. Risk Management - The company reported no significant risks affecting its operations during the reporting period[10]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[10]. - The company has not faced any violations in decision-making procedures regarding external guarantees[10]. - The company faces risks from intensified market competition in the raw materials and intermediates sector, particularly from emerging competitors in China and India[153]. - Regulatory changes in the pharmaceutical industry may increase operational costs and require the company to adapt quickly to avoid performance declines[154]. Environmental and Safety Measures - The company has enhanced its safety production and environmental protection measures, leading to significant reductions in hazardous waste disposal costs and overall production costs[42]. - The company emphasizes safety production and has implemented various safety management regulations to mitigate risks associated with hazardous materials[157]. - The company has established strict environmental control systems to comply with high regulatory standards, but may face increased costs due to stricter environmental policies[156]. Employee and Management Structure - The company has a total of 1,749 employees, with 388 in the parent company and 1,361 in major subsidiaries[195]. - The employee composition includes 1,005 production personnel, 463 technical personnel, and 17 sales personnel[195]. - The company has implemented a dual salary structure consisting of basic salary and performance-based salary, with performance pay linked to annual business results[196]. - The company provides various training programs to enhance employee skills, integrating internal and external resources[198]. Financial Management - The company completed a share buyback of 2,170,103 shares for a total amount of ¥54.99 million, aimed at optimizing the equity structure and demonstrating confidence in its long-term value[42]. - The company plans to use temporarily idle funds from convertible bonds for cash management, reflecting a proactive approach to liquidity management[182]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 6.6499 million yuan[174].

Financial Performance - The company's revenue for Q1 2025 reached ¥177,281,127.53, representing a 147.09% increase compared to ¥71,748,898.94 in the same period last year[4]. - Net profit attributable to shareholders was ¥1,644,942.52, a significant recovery from a loss of ¥10,837,428.95 in the previous year[4]. - Basic and diluted earnings per share improved to ¥0.02 from -¥0.11 in the same period last year[4]. - The company reported a comprehensive income total of ¥1,669,086.86 for Q1 2025, compared to a loss of ¥10,854,546.97 in Q1 2024[20]. - In Q1 2025, the company reported a net profit of ¥1,027,111.85, a significant improvement compared to a net loss of ¥5,249,851.02 in Q1 2024[29]. Cash Flow and Investments - The net cash flow from operating activities was -¥10,865,862.42, an improvement from -¥45,695,720.78 year-on-year[4]. - Cash flow from operating activities for Q1 2025 was ¥252,557,911.31, an increase from ¥150,682,611.69 in Q1 2024[22]. - The company reported a total of ¥626,146,476.44 in cash inflows from investing activities, a substantial rise from ¥150,325,813.93 in the previous period[24]. - The net cash flow from investing activities was ¥36,146,476.44, compared to ¥42,714,739.63 in the previous period, indicating a decrease[24]. - The cash and cash equivalents at the end of Q1 2025 totaled ¥210,488,756.74, up from ¥135,701,805.65 at the end of Q1 2024, reflecting an increase of approximately 55.2%[32]. Research and Development - Research and development (R&D) expenses totaled ¥33,249,709.23, up 35.73% from ¥24,497,483.11 in the previous year, accounting for 18.76% of revenue[4][5]. - Research and development expenses increased to ¥33,249,709.23 in Q1 2025, compared to ¥24,497,483.11 in Q1 2024, reflecting a growth of 36%[19]. - Research and development expenses for Q1 2025 were ¥25,096,510.98, up from ¥17,896,738.55 in Q1 2024, representing an increase of 40.3%[28]. Assets and Liabilities - Total assets decreased by 3.11% to ¥1,891,210,652.29 from ¥1,951,840,194.13 at the end of the previous year[5]. - Total current assets as of March 31, 2025, amount to ¥1,384,396,039.15, a decrease from ¥1,468,800,257.35 as of December 31, 2024[13][15]. - Total liabilities as of March 31, 2025, are ¥690,255,565.05, down from ¥750,352,169.32[15]. - The total liabilities decreased from ¥783,191,676.41 to ¥720,893,047.71, indicating a reduction of approximately 8%[16]. - The company's total assets decreased from ¥1,951,840,194.13 to ¥1,891,210,652.29, a decline of about 3%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,885[10]. - The largest shareholder, Wu Yaohua, holds 36,497,874 shares, representing 35.71% of total shares[10]. - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[11]. Operational Highlights - The significant increase in revenue was attributed to higher project deliveries in sectors such as construction machinery, chemicals, pharmaceuticals, printing, and new energy vehicles[8]. - The company plans to continue expanding its R&D efforts and improve cash flow management to support future growth[8]. - There are no other significant reminders regarding the company's operational situation during the reporting period[12].

广东东峰新材料集团股份有限公司2025 年第一季度报告 证券代码：601515 证券简称：东峰集团 1 / 18 广东东峰新材料集团股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | 变动幅度(%) | | 营业收入 | 295,660,510.82 | 354,984,405.88 | -16.71 | | 归属于上市公司股东的净利润 | -9,850,029.39 | 12, ...

Financial Performance - The company's operating revenue for 2024 reached CNY 3,492,507,758.73, an increase of 7.72% compared to CNY 3,242,343,470.61 in 2023[22] - The net profit attributable to shareholders for 2024 was CNY 240,493,449.06, reflecting a growth of 26.45% from CNY 190,184,140.79 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 228,601,890.90, up 25.25% from CNY 182,517,110.02 in 2023[22] - The net cash flow from operating activities for 2024 was CNY 414,504,926.18, an increase of 18.17% compared to CNY 350,780,647.47 in 2023[22] - The total assets at the end of 2024 amounted to CNY 3,360,614,930.49, a 14.51% increase from CNY 2,934,676,730.39 at the end of 2023[22] - The net assets attributable to shareholders reached CNY 1,837,255,641.25, which is a 12.63% increase from CNY 1,631,214,998.45 in 2023[22] - Basic earnings per share for 2024 were CNY 0.55, representing a 27.91% increase from CNY 0.43 in 2023[23] - The weighted average return on equity for 2024 was 13.98%, an increase of 1.66 percentage points from 12.32% in 2023[23] Revenue Breakdown - The company's total revenue for Q1 was approximately CNY 658.45 million, Q2 was CNY 1,138.35 million, Q3 was CNY 793.36 million, and Q4 was CNY 902.35 million[25] - Net profit attributable to shareholders for Q1 was CNY 39.02 million, Q2 was CNY 91.05 million, Q3 was CNY 70.22 million, and Q4 was CNY 40.21 million[25] - The net cash flow from operating activities in Q1 was negative CNY 203.83 million, while Q2 was positive CNY 266.72 million, Q3 was CNY 17.35 million, and Q4 was CNY 334.26 million[25] Business Operations - The company focuses on industrial module design and manufacturing, providing customized project construction services across various industries, including chemical, oil and gas, mining, and water treatment[40] - The company’s engineering services include EPC, engineering design, procurement, modularization, construction, and maintenance, providing a full-service capability[32] - The company has established long-term relationships with major multinational clients such as BASF and Honeywell, enhancing its market reputation[35] - The company has a comprehensive capability in the design and manufacturing of large industrial modules, ensuring customized project construction services[31] Research and Development - Research and development expenses rose by 64.21% to 77,688,492.33 RMB, indicating increased investment in innovation[58] - The company employed 204 R&D personnel, representing 9.94% of the total workforce[72] - The company is investing 50 million in R&D for new technologies aimed at enhancing user experience and operational efficiency[112] Environmental and Safety Measures - The company has achieved ISO 14001:2015 environmental management system certification, demonstrating its commitment to environmental protection[152] - The company has implemented measures to control pollutants generated during production, including the use of dust collectors and purification towers for waste gas treatment[152] - The company has developed an emergency response plan for environmental incidents, ensuring preparedness and effective response to potential environmental emergencies[149] Shareholder and Governance - The company plans to distribute a cash dividend of CNY 1.13 per 10 shares, subject to approval at the 2024 annual general meeting[6] - The total cash dividend amount (including tax) for the current period is 85,162,599 CNY, accounting for 35.41% of the net profit attributable to ordinary shareholders[136] - The company has a cash dividend policy aimed at providing stable returns to shareholders, with a plan for the next three years (2023-2025)[133] - The company has a structured approach to managing solid waste, ensuring proper disposal of hazardous and non-hazardous materials[153] Market Expansion and Strategy - The company aims to expand its industrial module design and manufacturing business, focusing on sectors such as oil and gas, mining, and water treatment, leveraging the growing trend towards modular construction[92] - Market expansion plans include entering two new international markets by Q2 2024, projected to increase overall market share by 5%[112] - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of up to 100 million allocated for potential deals[112] Risks and Challenges - The company faces procurement price volatility risks, particularly in materials and labor, which constitute a high proportion of costs[101] - Environmental and safety production risks are present, with potential penalties if the company fails to comply with regulations[102] - Talent retention is critical, as competition for skilled personnel may lead to project delays and quality issues if key staff leave[102] Financial Management - The company is seeking bank credit limits for 2024, reflecting its strategy for financial flexibility[109] - The company has engaged in cash asset management, with investments in bank wealth management products totaling RMB 230,000,000 and brokerage wealth management products totaling RMB 281,243,470[186] - The company has not faced any delisting risks or bankruptcy restructuring matters during the reporting period[179]

Financial Performance - The company's revenue for Q1 2025 reached ¥43,005,484.73, representing a 49.31% increase compared to ¥28,803,048.98 in the same period last year[2] - The net profit attributable to shareholders was -¥22,743,420.04, an improvement of 21.49% from -¥28,967,442.68 year-on-year[2] - Total operating revenue for Q1 2025 was CNY 43,005,484.73, an increase of 49.5% compared to CNY 28,803,048.98 in Q1 2024[16] - Operating profit for Q1 2025 was a loss of CNY 25,746,292.62, improved from a loss of CNY 31,194,936.08 in Q1 2024[17] - Net profit for Q1 2025 was a loss of CNY 22,864,145.10, compared to a loss of CNY 29,729,571.97 in Q1 2024, showing a 23.2% improvement[17] Cash Flow - The net cash flow from operating activities improved by 35.74%, amounting to -¥18,941,859.09, primarily due to government subsidies related to assets received during the reporting period[5] - The net cash flow from operating activities was -$18,941,859.09, compared to -$29,477,526.22 in the previous period, indicating an improvement[21] - Cash inflow from investment activities totaled $149,961,811.71, down from $296,028,946.12 year-over-year[21] - The net cash flow from investment activities was -$96,219,095.19, contrasting with a positive $227,558,712.64 in the prior period[21] - Cash inflow from financing activities was $4,000,000.00, compared to $3,058,488.36 previously[22] - The net cash flow from financing activities was -$2,797,632.23, an improvement from -$9,375,489.11 in the last period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,603,599,576.78, a decrease of 0.90% from ¥1,618,129,841.84 at the end of the previous year[3] - Current assets totaled RMB 832,720,710.75, slightly down from RMB 833,404,226.85, indicating a decrease of about 0.08%[11] - The company's total liabilities amounted to RMB 72,977,200.08, down from RMB 83,995,703.30, a decrease of about 13.1%[13] - The total liabilities increased to CNY 142,449,057.99 in Q1 2025 from CNY 131,788,713.04 in Q1 2024, reflecting an increase of 7.9%[16] - Total equity attributable to shareholders decreased to CNY 1,440,715,532.79 in Q1 2025 from CNY 1,465,785,417.74 in Q1 2024, a decline of 1.7%[16] Research and Development - Research and development expenses totaled ¥21,188,472.96, accounting for 49.27% of revenue, down from 77.43% in the previous year[2] - Research and development expenses for Q1 2025 were CNY 21,188,472.96, slightly down from CNY 22,301,183.25 in Q1 2024[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,939[6] - The largest shareholder, Beijing Kangwei Century Biotechnology Co., Ltd., holds 44.80% of the shares, totaling 50,400,000 shares[7] - The company has not disclosed any significant changes in shareholder relationships or actions regarding stock lending or borrowing[9] Market and Product Development - The company reported a significant increase in revenue from technology service segments, particularly in sequencing technology and gene synthesis services[5] - The company has plans for market expansion and new product development, focusing on enhancing its technology service offerings[5]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 202,449,804.82, a decrease of 3.02% compared to CNY 208,748,232.76 in the same period last year[3] - Net profit attributable to shareholders was CNY 33,024,491.25, reflecting a 2.58% increase from CNY 32,194,759.85 year-on-year[3] - Total operating revenue for Q1 2025 was CNY 202,449,804.82, a decrease of 3.1% compared to CNY 208,748,232.76 in Q1 2024[18] - Net profit for Q1 2025 increased to CNY 37,354,706.91, compared to CNY 34,661,088.13 in Q1 2024, representing a growth of 7.8%[19] - Operating profit for Q1 2025 was CNY 39,931,799.65, up from CNY 37,480,676.43 in Q1 2024, indicating an increase of 6.5%[19] - Basic and diluted earnings per share were both CNY 0.0274, up 2.62% from CNY 0.0267 in the previous year[3] - Basic and diluted earnings per share for the period were both ¥0.0274, slightly up from ¥0.0267 in the previous year[20] Cash Flow and Investments - The net cash flow from operating activities surged by 95.06%, reaching CNY 70,895,599.24, primarily due to the release of bank guarantees and frozen funds[6] - In Q1 2025, the company reported a net cash flow from operating activities of ¥70,895,599.24, an increase of 95.0% compared to ¥36,345,900.06 in Q1 2024[22] - The total cash inflow from operating activities was ¥291,898,967.66, up from ¥234,614,224.99 in the previous year, reflecting a growth of 24.4%[23] - The company recorded a net cash outflow from investing activities of ¥33,859,267.07, an improvement from a net outflow of ¥51,310,753.61 in Q1 2024[23] - The company’s cash outflow for operating activities totaled ¥221,003,368.42, compared to ¥198,268,324.93 in the previous year, reflecting a rise of 11.4%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,219,239,055.35, down 2.10% from CNY 5,331,379,227.76 at the end of the previous year[4] - The company's total assets as of March 31, 2025, were CNY 5,219,239,055.35, a decrease from CNY 5,331,379,227.76 as of December 31, 2024[14] - Total liabilities decreased to CNY 770,488,916.48 as of March 31, 2025, from CNY 830,429,687.17 at the end of 2024[15] - The company's equity attributable to shareholders was CNY 4,273,931,026.66 as of March 31, 2025, down from CNY 4,334,362,916.97 at the end of 2024[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 64,235, with 35,062 A-share and 29,173 B-share holders[8] - The largest shareholder, Hunan Ningrui Investment Partnership, held 141,528,801 shares, representing 11.73% of the total shares[8] Research and Development - Research and development expenses for Q1 2025 were CNY 5,045,274.87, compared to CNY 4,699,455.22 in Q1 2024, reflecting an increase of 7.4%[19] Other Income and Expenses - Non-recurring gains and losses totaled CNY 1,746,565.80, with significant contributions from government subsidies and asset disposals[5] - Other comprehensive income after tax for Q1 2025 was CNY -89,554,107.63, compared to CNY -46,512,664.73 in Q1 2024, indicating a decline in comprehensive income[19] - The total comprehensive income attributable to the parent company was a loss of ¥56,529,616.38, compared to a loss of ¥14,317,904.88 in the same period last year[20] Tax and Borrowings - The company received tax refunds of ¥4,237,850.21 in Q1 2025, significantly higher than ¥1,956,278.07 in Q1 2024, marking an increase of 116.5%[23] - The company raised ¥30,000,000.00 through borrowings in Q1 2025, compared to ¥25,000,000.00 in Q1 2024, representing a 20.0% increase[24] Market and Product Development - The company did not report any significant new product developments or market expansion strategies during this quarter[10]